TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is today a growing need for culturally adapted initiatives among immigrants to prevent and treat T2D. Others have failed to increase the level of physical activity in this sedate group. The investigators believe this is due to missing assistance and lack of influence from the Pakistani milieu. To improve this, a culturally adapted physical activity will be established in this project in close cooperation with the Pakistanis themselves.

Through this program it is the investigators' goal to increase their physical activity level and prevent lifestyle diseases among Pakistanis in Oslo with a high risk of developing these diseases.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
B: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
C: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A
D: Arm Label: CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health educational program | Arm Label: IG; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity intervention | Intervention Type: BEHAVIORAL; Name: Physical activity intervention; Assigned to Arm(s): IG | Intervention Type: BEHAVIORAL; Name: Health educational program; Assigned to Arm(s): CG

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is today a growing need for culturally adapted initiatives among immigrants to prevent and treat T2D. Others have failed to increase the level of physical activity in this sedate group. The investigators believe this is due to missing assistance and lack of influence from the Pakistani milieu. To improve this, a culturally adapted physical activity will be established in this project in close cooperation with the Pakistanis themselves.

Through this program it is the investigators' goal to increase their physical activity level and prevent lifestyle diseases among Pakistanis in Oslo with a high risk of developing these diseases.


Options:
A: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2
D: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial
Brief Summary: We investigate the efficacy of probiotics in reducing the incidence and severity of necrotizing enterocolitis (NEC) for very low birth weight (VLBW) infants.A prospective, masked, multi-center randomized control trial will be conducted level III neonatal center to evaluate the beneficial effects of probiotics for NEC among VLBW (\<1500 g) infants. VLBW infants who start to feed enterally are eligible and are randomized into 2 groups after parental informed consents were obtained. Infants in the study group are fed with Infloran (Lactobacillus acidophilus and Bifidobacterium bifidus) with breast or formula milk twice daily for 6 weeks. Infants in the control group are fed with breast or formula milk alone. The clinicians caring for the infants are blinded to the group assignment. The primary outcome measurement is death or NEC (≧stage 2).


Options:
A: Arm Label: Lactobacillus PS11603 & Bifidobacterium PS10402; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus PS11603 & Bifidobacterium PS10402 | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus PS11603 & Bifidobacterium PS10402; Assigned to Arm(s): Lactobacillus PS11603 & Bifidobacterium PS10402 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG ); Assigned to Arm(s): N/A
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: infloran | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2
D: Arm Label: Lactobacillus reuteri; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus reuteri | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-negative Metastatic Breast Cancer
Brief Summary: The purpose of this clinical trial was to determine whether combining iniparib (BSI-201) with standard chemotherapy in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer patients improve clinical benefit compared to treatment with standard chemotherapy alone.

Based on data generated by BiPar/Sanofi, it was concluded that iniparib does not possess characteristics typical of the poly (ADP-ribose) polymerase (PARP) inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.


Options:
A: Arm Label: talazoparib; Type: EXPERIMENTAL; Interventions: Drug: talazoparib | Arm Label: Physician's-Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's-Choice | Intervention Type: DRUG; Name: talazoparib; Assigned to Arm(s): talazoparib | Intervention Type: DRUG; Name: Physician's-Choice; Assigned to Arm(s): Physician's-Choice
B: Arm Label: talazoparib; Type: EXPERIMENTAL; Interventions: Drug: talazoparib | Intervention Type: DRUG; Name: talazoparib; Assigned to Arm(s): talazoparib
C: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: iniparib; Assigned to Arm(s): Arm G/C/I
D: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: Iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: Iniparib; Assigned to Arm(s): Arm G/C/I

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus
Brief Summary: Although intensive medical treatment of diabetes has clearly been demonstrated to be worthwhile, it has not been a total success in diabetes treatment for a variety of reasons including lack of response to medication. Diabetes has been well demonstrated as a co-morbidity illness of obesity patients. In observation, with exclusion stomach and duodenum of bariatric surgery (gastric bypass), most morbidly obese patients (about 80%) with diabetes had a significant improved of sugar control. Base of this observation, we will try to find out the role surgical intervention (gastric bypass \& sleeve gastrectomy) in obese-related diabetes.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: sleeve gastrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-Y-gastric bypass | Intervention Type: PROCEDURE; Name: sleeve gastrectomy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Roux-Y-gastric bypass; Assigned to Arm(s): B
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: intensive medical management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RYGB & IMM | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RYGB & IMM; Assigned to Arm(s): 2
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: gastric bypass | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: sleeve gastrectomy | Intervention Type: PROCEDURE; Name: gastric bypass; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: sleeve gastrectomy; Assigned to Arm(s): 3
D: Arm Label: Bariatric surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery | Arm Label: Intensive lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Bariatric surgery | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.
Brief Summary: The purpose of this study is to determine whether intra-arterial rt-PA within 6 hours from an ischemic stroke onset, compared with intravenous infusion of the same drug within 3 hours, increases the proportion of independent survivors at 3 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
B: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
C: Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Arm Label: IV rtPA and IA Penumbra System; Type: EXPERIMENTAL; Interventions: Device: Penumbra System | Intervention Type: DRUG; Name: intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV rtPA | Intervention Type: DEVICE; Name: Penumbra System; Assigned to Arm(s): IV rtPA and IA Penumbra System
D: Arm Label: IV thrombolysis + thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase (rt-PA)/Actilyse, Procedure: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE) | Arm Label: IV thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase (rt-PA)/Actilyse | Intervention Type: DRUG; Name: Alteplase (rt-PA)/Actilyse; Assigned to Arm(s): IV thrombolysis, IV thrombolysis + thrombectomy | Intervention Type: PROCEDURE; Name: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE); Assigned to Arm(s): IV thrombolysis + thrombectomy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.
Brief Summary: The purpose of this study is to determine whether intra-arterial rt-PA within 6 hours from an ischemic stroke onset, compared with intravenous infusion of the same drug within 3 hours, increases the proportion of independent survivors at 3 months.


Options:
A: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
D: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.
Brief Summary: The purpose of this study is to determine whether intra-arterial rt-PA within 6 hours from an ischemic stroke onset, compared with intravenous infusion of the same drug within 3 hours, increases the proportion of independent survivors at 3 months.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
C: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.
Brief Summary: The purpose of this study is to determine whether intra-arterial rt-PA within 6 hours from an ischemic stroke onset, compared with intravenous infusion of the same drug within 3 hours, increases the proportion of independent survivors at 3 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2
B: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
D: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation
Brief Summary: The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.


Options:
A: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter
B: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
C: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A